Gounder, M. M., Bauer, T. M., Schwartz, G. K., Weise, A. M., LoRusso, P., Kumar, P., Tao, B., Hong, Y., Patel, P., Lu, Y., Lesegretain, A., Tirunagaru, V. G., Xu, F., Doebele, R. C., & Hong, D. S. (2023). A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas. Journal of Clinical Oncology, 41(9), 1714–1724. https://doi.org/10.1200/jco.22.01285